Literature DB >> 9669391

Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma.

E C Glass1, R Essner, D L Morton.   

Abstract

UNLABELLED: Although lymphoscintigraphy is commonly used for the preoperative evaluation of patients with cutaneous melanoma and for intraoperative identification of sentinel lymph nodes, there is no consensus regarding the most useful radiopharmaceuticals or imaging times.
METHODS: Fifty-one consecutive patients with clinical American Joint Committee on Cancer Stage I or II melanoma were assigned to one of three groups of 17 for lymphoscintigraphy with one of three radiopharmaceuticals: 99mTc-albumin colloid (AC), 99mTc-human serum albumin (HSA) or 99mTc-sulfur colloid (SC). Colloidal agents were filtered through 0.2 microm filters. After injecting 18.5-30 MBq (500-800 microCi) of the radiopharmaceutical, dynamic monitoring over injection sites and node basins was performed to identify draining lymphatic channels and sentinel nodes. In addition, static digital and analog images were acquired from the injection site and draining node basins immediately after injection and at 30 min (early) and 2 to 4 hr (delayed) after injection. Dynamic and static images were analyzed to determine transit times to the sentinel node, the number of nodes visualized in early and delayed images, the quality of lymph node and lymph channel visualization, the sentinel-to-nonsentinel uptake ratios and the washout rates from injection sites.
RESULTS: Early images with all three agents provided reliable identification of sentinel lymph nodes. Technetium-99m-HSA demonstrated faster washout rates from injection sites and better definition of lymph channels than either particulate agent, whereas particulate agents were retained longer in nodes and demonstrated more nodes in delayed images than in early images. All agents demonstrated lymph channels better in early images than in delayed images. In general, variations between patients exceeded differences between agents. Sentinel nodes could not be distinguished reliably from nonsentinel nodes in delayed images alone.
CONCLUSION: All three agents are acceptable for cutaneous lymphoscintigraphy, but reliable identification of sentinel nodes and their afferent lymph channels requires early imaging. Delayed imaging or localization alone is unreliable and may lead to incorrect identification of the sentinel node.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669391

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

Review 1.  Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute.

Authors:  Sanjay P Bagaria; Mark B Faries; Donald L Morton
Journal:  J Surg Oncol       Date:  2010-06-15       Impact factor: 3.454

Review 2.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

3.  (68)Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes.

Authors:  Renata Madru; Thuy A Tran; Johan Axelsson; Christian Ingvar; Adnan Bibic; Freddy Ståhlberg; Linda Knutsson; Sven-Erik Strand
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

4.  EANM-EORTC general recommendations for sentinel node diagnostics in melanoma.

Authors:  Annette H Chakera; Birger Hesse; Zeynep Burak; James R Ballinger; Allan Britten; Corrado Caracò; Alistair J Cochran; Martin G Cook; Krzysztof T Drzewiecki; Richard Essner; Einat Even-Sapir; Alexander M M Eggermont; Tanja Gmeiner Stopar; Christian Ingvar; Martin C Mihm; Stanley W McCarthy; Nicola Mozzillo; Omgo E Nieweg; Richard A Scolyer; Hans Starz; John F Thompson; Giuseppe Trifirò; Giuseppe Viale; Sergi Vidal-Sicart; Roger Uren; Wendy Waddington; Arturo Chiti; Alain Spatz; Alessandro Testori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10       Impact factor: 9.236

5.  EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma.

Authors:  Christina Bluemel; Ken Herrmann; Francesco Giammarile; Omgo E Nieweg; Julien Dubreuil; Alessandro Testori; Riccardo A Audisio; Odysseas Zoras; Michael Lassmann; Annette H Chakera; Roger Uren; Sotirios Chondrogiannis; Patrick M Colletti; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-25       Impact factor: 9.236

6.  Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.

Authors:  Donald L Morton; Alistair J Cochran; John F Thompson; Robert Elashoff; Richard Essner; Edwin C Glass; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; He-jing Wang
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

Review 7.  Current status of sentinel lymph-node biopsy in patients with breast cancer.

Authors:  Gang Cheng; Stephanie Kurita; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-11       Impact factor: 9.236

Review 8.  The role of sentinel lymph node biopsy in the management of melanoma.

Authors:  Farin Amersi; Donald L Morton
Journal:  Adv Surg       Date:  2007

9.  Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma.

Authors:  L W T Alkureishi; Z Burak; J A Alvarez; J Ballinger; A Bilde; A J Britten; L Calabrese; C Chiesa; A Chiti; R de Bree; H W Gray; K Hunter; A F Kovacs; M Lassmann; C R Leemans; G Mamelle; M McGurk; J Mortensen; T Poli; T Shoaib; P Sloan; J A Sorensen; S J Stoeckli; J B Thomsen; G Trifiro; J Werner; G L Ross
Journal:  Ann Surg Oncol       Date:  2009-11       Impact factor: 5.344

10.  Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma.

Authors:  Lee W T Alkureishi; Zeynep Burak; Julio A Alvarez; James Ballinger; Anders Bilde; Alan J Britten; Luca Calabrese; Carlo Chiesa; Arturo Chiti; Remco de Bree; Harry W Gray; Keith Hunter; Adorjan F Kovacs; Michael Lassmann; C Rene Leemans; Gerard Mamelle; Mark McGurk; Jann Mortensen; Tito Poli; Taimur Shoaib; Philip Sloan; Jens A Sorensen; Sandro J Stoeckli; Jorn B Thomsen; Giusepe Trifiro; Jochen Werner; Gary L Ross
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.